对接受他莫昔芬治疗的墨西哥东南部患者的无乳腺癌生存期没有影响。
does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment.
作者信息
Jorge-Aarón Rangel-Méndez, Rodrigo Rubi-Castellanos, de Jesús Ascencio-Montiel Iván, Esther Moo-Puc Rosa
机构信息
Unidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Hospital de Especialidades del Centro Médico Nacional 'Ignacio García Téllez', Instituto Mexicano del Seguro Social, Calle 41 No. 439, Col. Industrial, 97150 Mérida, Yucatán, México.
Centro de Investigaciones Regionales 'Dr Hideyo Noguchi' Calle 96 S/N, Avenida Jacinto Canek y calle 47, Paseo de las Fuentes, 97225 Mérida, Yucatán, México.
出版信息
Per Med. 2020 Jul 1;17(4):261-270. doi: 10.2217/pme-2019-0135. Epub 2020 Jun 26.
We conducted a retrospective analysis in 71 Mexican Mestizo patients to evaluate the breast cancer-free survival (BCFS) among the inferred genetic phenotypes (GP) of . was genotyped through Taqman-probe analysis; GP were inferred according to international guidelines. The BCFS was estimated through Kaplan-Meier method and analyzed with a log-rank test; hazard ratios were calculated with 95% CI and p < 0.05. The BCFS did not differ among GP (p = 0.45) and recurrence risk was similar between gNM + gUM and gPM + gIM groups (hazard ratio: 1.54, 95% CI: 0.37-6.38; p = 0.55). The findings do not support any impact of on BCFS. Evaluation of other genetic/nongenetic biomarkers is needed in Mexican Mestizo patients under tamoxifen treatment.
我们对71名墨西哥梅斯蒂索患者进行了回顾性分析，以评估推断的遗传表型（GP）中的无乳腺癌生存期（BCFS）。通过Taqman探针分析对……进行基因分型；根据国际指南推断GP。通过Kaplan-Meier方法估计BCFS，并使用对数秩检验进行分析；计算风险比及其95%置信区间，p<0.05。不同GP之间的BCFS无差异（p = 0.45），gNM + gUM组和gPM + gIM组之间的复发风险相似（风险比：1.54，95%置信区间：0.37 - 6.38；p = 0.55）。研究结果不支持……对BCFS有任何影响。对于接受他莫昔芬治疗的墨西哥梅斯蒂索患者，需要评估其他遗传/非遗传生物标志物。
Zotero 插件